文献速递流行病学与生物统计临床试验与 GCP

比较限制性平均生存时间时自适应群序贯设计的样本量重估

Sample Size Recalculation in Adaptive Group Sequential Study Designs for Comparing Restricted Mean Survival Times.
PubMed 文献 · Stat Med · 2026-01-01

在非比例风险场景下,限制性平均生存时间(RMST)日益被推荐用于量化疗效。本文针对以RMST为主要终点的自适应群序贯设计,详细阐述样本量重估方法,并通过模拟研究比较其与常用终点在延迟治疗效应下的表现,指出所描述的组合检验也可用于样本量以外的其他适应性调整。

要点

  • 非比例风险时RMST比风险比更合适,但规划期需多个冗余参数估计,易导致检验效能不足。
  • 自适应群序贯设计允许在试验进行中重估样本量,以应对规划期参数不确定性。
  • 所描述的组合检验不仅可用于样本量重估,也可用于其他适应性调整。

核心结论

  • 以RMST为主要终点的自适应群序贯设计在延迟治疗效应场景下的样本量重估方法被完整阐述,模拟研究比较了其与常用终点的表现。

研究设计与样本

  • 方法学工作,通过大规模模拟研究比较以RMST为主要终点的自适应设计与常用终点在延迟治疗效应下的表现。

主要发现

  • 规划期冗余参数估计不精确可能导致检验效能不足,自适应样本量重估可应对此不确定性。
  • 所描述的组合检验也可用于样本量以外的其他适应性调整。

临床怎么用

  • 在预期非比例风险(如延迟治疗效应)的临床试验中,可考虑以RMST为主要终点并采用自适应群序贯设计进行样本量重估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-proportional hazards cases are frequently expected in clinical trials with time-to-event endpoints (e.g., cardiology, oncology). The relevance of hazard ratios to quantify the treatment effect is questionable and potentially misleading in this context. Hence, alternative methods comparing restricted mean survival times are increasingly promoted. Specific challenges arise when planning clinical trials for comparing restricted mean survival times, as several nuisance parameter estimates are needed for calculating the sample size. Precise estimates might be difficult to obtain at the planning stage and might lead to underpowered trials. One way of dealing with this insecurity is to apply adaptive group sequential study designs with the option to adapt the sample size during an ongoing trial. Within this work, we consider such sample size adaptations, with a specific focus on the context of delayed treatment effects. We compare the performance of an adaptive design with the restricted mean survival time as the primary endpoint with other commonly chosen endpoints in this scenario by means of an extensive simulation study. With our proposed method, adaptive designs with the restricted mean survival time as the primary endpoint are now thoroughly explained. The combination test that we describe can also be useful for other adaptations than sample sizes.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Herrmann C, Blanche P. Sample Size Recalculation in Adaptive Group Sequential Study Designs for Comparing Restricted Mean Survival Times. Stat Med. 2026. PMID: 41851043. doi:10.1002/sim.70490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。